Drugs / BCMA-specific CAR T-cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03502577 | May 2018 → Apr 2022 | plasma cell myeloma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA-specific CAR T-cells | “Participants then receive BCMA-specific CAR T-cells intravenously (IV) over 20-30 minutes on day 0” NCT03502577 ↗ |
| Action | Deplete | “enhance the killing of cancer cells” NCT03502577 ↗ |
| Modality | Cell therapy | “B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T Cells” NCT03502577 ↗ |
| Route | Intravenous | “Participants then receive BCMA-specific CAR T-cells intravenously (IV) over 20-30 minutes on day 0” NCT03502577 ↗ |